title: Significance of erb-B2 immunoreactivity in cervical cancer.
abstract: C-erbB2 is over-expressed or amplified in many carcinomas. We assessed the relationship between erb-B2 immunoreactivity, and its predictive role in progression-free survival and treatment outcome in patients with cervical carcinoma. Sections from 65 cervical carcinoma were immunostained with antibody to p185 erbB2. Immunoreactive ErbB2 was found in 25 patients (38%) [+ 15 pts. (23%); ++ 10 pts. (15%)]. There were no correlation with age, performance status, grading and histology. Erb-B2 immunoreactivity significantly correlated with stage of the disease. Positive immunoreactivity was found in 63%, 44%, 14% and 0% of stage I, II, III and IV carcinomas, (p = 0.0045). Progression-free survival was longer in erb-B2 positive patients without reaching significance. No correlation was found between erbB2 and response to radiotherapy or chemotherapy. In conclusion, a significant proportion of stage I and II cervical cancer express erb-B2 compared to more advanced stages. Expression of the oncogene does not appear to be related to prognosis or treatment outcome.
authors.affiliation: Division of Experimental Oncology E, National Cancer Institute, Naples, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Califano
authors.forename: Simona
authors.initials: S
authors.lastname: Losito
authors.forename: Carmela
authors.initials: C
authors.lastname: Pisano
authors.forename: Giovanni
authors.initials: G
authors.lastname: Santelli
authors.forename: Stefano
authors.initials: S
authors.lastname: Greggi
authors.forename: Francesco
authors.initials: F
authors.lastname: Iodice
authors.forename: Giovanni
authors.initials: G
authors.lastname: DiVagno
authors.forename: Giustino
authors.initials: G
authors.lastname: Silvestro
authors.forename: Rosa
authors.initials: R
authors.lastname: Tambaro
authors.forename: Roberta
authors.initials: R
authors.lastname: Formato
authors.forename: Vincenzo Rosario
authors.initials: VR
authors.lastname: Iaffaioli
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
authors.forename: Sandro
authors.initials: S
authors.lastname: Pignata
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000096:biosynthesis*; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases